Zusammenfassung
Die Therapie von Patienten mit fortgeschrittenen gastrointestinalen Tumoren ist nach wie vor in vielen Bereichen experimentell und nicht durch valide randomisierte Studien nach den Kriterien der »evidence based medicine« begründet. Dies ist insofern erstaunlich, als gastrointestinale Tumoren zu den häufigsten Malignomen in der westlichen Welt gehören. Eine der Ursachen für das Fehlen gut begründeter Standardtherapien ist, dass gastrointestinale Tumoren eine Reihe molekulargenetischer und zellbiologischer Besonderheiten aufweisen, die ihre Therapie mit konventionellen chemotherapeutischen Prinzipien erschweren.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Ahnen DJ (1996) Stalking the guardian of the genome: p53 in colorectal carcinogenesis. Am J Gastroenterol 91: 3–6
Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91: 854–862
Choi SH, Takahashi K, Eto H, Yoon SS, Tanabe KK (2000) CD44 s expression in human colon carcinomas influences growth of liver metastases. Int J Cancer 85: 523–526
D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P (2001) Differential expression of protease-activated receptors-1 and-2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol 158: 2031–2041
D'Arpa P, Liu LF (1995) Cell cycle-specific and transcription-related phosphorylation of mammalian topoisomerase I. Exp Cell Res 217: 125–131
de Gramont A, Vignoud J, Tournigand C et al. (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214–219
Deutsches Krebsforschungszentrum, Heidelberg www.dkfzheidelberg.de
Dippold W, Wittig B, Schwaeble W, Mayet W, Meyer zum Buschenfelde KH (1993) Expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in colonic epithelial cells. Gut 34: 1593–1597
Even-Ram SC, Maoz M, Pokroy E et al. (2001) Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. J Biol Chem 276: 10952–10962
Ghoshal K, Jacob ST (1997) An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol 53: 1569–1575
Gieseler F (2000) The dilemma of gastroenterological oncology: we know a lot but we still achieve too little. Int J Colorectal Dis 15: 112–113
Gieseler F (2000) Inhibition der Mikrometastasierung durch Dalteparin bei Patienten mit Kolonkarzinomen im Stadium Dukes C nach R0-Resektion. Arbeitsgemeinschaft Gastroenterologische Onkologie der Deutschen Gesellschaft für Verdauungs-und Stoffwechselkrankheiten (DGVS) Protokoll Nr.: 39
Gieseler F, Nuessler VV (1999) Apoptosis research is saving the reputation of chemotherapy. Leukemia 13: 1860
Gompertz B (1825) On the nature of the function expressive of the law of human mortality and the new mode of determining the value of life contigencies. Phil Trans R Soc Lond (Biol) 115: 513–585
Hinz B, Brune K (1999) Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances. Wien Klin Wochenschr 111: 103–112
Hoffman K, Glimelius B (1998) Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer. Acta Oncol 37: 651–659
Kellner U, Rudolph P, Parwaresch R (2000) Human DNA-Topoisomerases — Diagnostic and therapeutic implications for cancer. Onkologie 23: 424–40
Kim J, Yu W, Kovalski K, Ossowski L (1998) Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94: 353–362
Kim WH, Yeo M, Kim MS et al. (2000) Role of caspase-3 in apoptosis of colon cancer cells induced by nonsteroidal antiinflammatory drugs. Int J Colorectal Dis 15: 105–111
Kozwich DL, Kramer LC, Mielicki WP, Fotopoulos SS, Gordon SG (1994) Application of cancer procoagulant as an early detection tumor marker. Cancer 74: 1367–1376
Marchan V, Moreno V, Pedroso E, Grandas A (2001) Towards a better understanding of the cisplatin mode of action. Chemistry 7: 808–815
Norton L, Simon R (1986) The Norton-Simon-hypothesis revisited. Cancer Treat Rep 70: 163–169
Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61: 1307–1317
Plunkett W, Huang P, Xu YZ (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22: 3–10
Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17: 2412–2418
Reddy BS (1999) Prevention of colon carcinogenesis by components of dietary fiber. Anticancer Res 19: 3681–3683
Rosen LS (1998) Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Huntingt) 12: 103–109
Saltz LB, Cox JV, Blanke C et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905–914
Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL (2001) Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal Cancer. New Engl J Med 345: 144–145
Sigal A, Rotter V (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60: 6788–6793
Smalley W, Ray WA, Daugherty J, Griffin MR (1999) Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 159: 161–166
Streit M, Schmidt R, Hilgenfeld RU, Thiel E, Kreuser ED (1996) Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. Recent Results Cancer Res 142: 19–50
Van Cutsem E, Peeters M (1999) Developments in fluoropyrimidine therapy for gastrointestinal cancer. Curr Opin Oncol 11: 312–317
Vogelstein B, Fearon ER, Hamilton SR et al. (1987) Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res 47: 4806–4813
von Tempelhoff GF, Harenberg J, Niemann F et al. (2000) Effect of low molecular weight heparin (Certoparin) vs unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. Int J Oncol 16: 815–824
Waters JS, Ross PJ, Popescu RA, Cunningham D (1997) New approaches to the treatment of gastro-intestinal cancer. Digestion 58: 508–519
Wolmark N, Rockette H, Mamounas E et al. (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17: 3553–3559
Wu XP, Dolnick BJ (1993) 5-Fluorouracil alters dihydrofolate reductase pre-mRNA splicing as determined by quantitative polymerase chain reaction. Mol Pharmacol 44: 22–29
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Gieseler, F. (2005). Grundlagen der Chemotherapie. In: Caspary, W.F., Mössner, J., Stein, J. (eds) Therapie gastroenterologischer Krankheiten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26660-7_60
Download citation
DOI: https://doi.org/10.1007/3-540-26660-7_60
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-44174-8
Online ISBN: 978-3-540-26660-0
eBook Packages: Medicine (German Language)